Theravance Biopharma TBPH Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's operating lease right-of-use assets in other assets?
- Theravance Biopharma (TBPH) reported operating lease right-of-use assets in other assets of $23M in Q1 2026.
- How has Theravance Biopharma's operating lease right-of-use assets in other assets changed year-over-year?
- Theravance Biopharma's operating lease right-of-use assets in other assets decreased by 16.1% year-over-year, from $27.43M to $23M.
- What is the long-term trend for Theravance Biopharma's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Theravance Biopharma's operating lease right-of-use assets in other assets has grown at a -10.8% compound annual growth rate (CAGR), from $43.26M to $24.37M.